CAM
ALXO icon

Cormorant Asset Management’s ALX Oncology ALXO Stock Holding History

Cormorant Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,142,079
Closed -$35M – 50
2024
Q1 		$35M Hold
3,142,079
– – 1.54% 19
2023
Q4 		$46.8M Buy
3,142,079
+2,530,000
+413% +$24M 2.23% 11
2023
Q3 		$2.94M Hold
612,079
– – 0.17% 43
2023
Q2 		$4.6M Hold
612,079
– – 0.26% 51
2023
Q1 		$2.77M Hold
612,079
– – 0.18% 58
2022
Q4 		$6.9M Sell
612,079
-100,000
-14% -$1.12M 0.46% 46
2022
Q3 		$6.82M Hold
712,079
– – 0.48% 47
2022
Q2 		$5.76M Hold
712,079
– – 0.44% 50
2022
Q1 		$12M Sell
712,079
-50,000
-7% -$854K 0.92% 31
2021
Q4 		$16.4M Sell
762,079
-250,000
-25% -$10.8M 0.97% 29
2021
Q3 		$74.8M Buy
1,012,079
+122,625
+14% +$8.17M 3.04% 9
2021
Q2 		$48.6M Buy
889,454
+7,684
+0.9% +$460K 1.65% 16
2021
Q1 		$65M Hold
881,770
– – 1.45% 15
2020
Q4 		$76M Sell
881,770
-90,000
-9% -$5.41M 1.81% 15
2020
Q3 		$36M Buy
+971,770
New +$38.2M 1.38% 24

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cormorant Asset Management's ALXO Position: Q2 2024 in Review

Cormorant Asset Management sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 3,142,079 shares — an estimated $35M sold.

Cormorant Asset Management first reported a position in ALXO in Q3 2020 and held it in 15 quarters. The position peaked at $76M in Q4 2020. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Cormorant Asset Management reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 3,142,079 ALX Oncology shares in Q2 2024, an estimated $35M.
  • Cormorant Asset Management first reported a position in ALX Oncology in Q3 2020 and held it in 15 quarters.
  • Cormorant Asset Management's ALX Oncology position peaked at $76M in Q4 2020.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.